Clinical Trial Update: A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating SCO-101 in combination with FOLFIRI for metastatic colorectal cancer with acquired resistance to FOLFIRI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• SCO-101

Snippet

Sponsor: Scandion Oncology A/S | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: UNKNOWN